CYDY
wenn nur 50% zutreffen...
Truth about CytoDyn-Leronlimab-PRO140(Vyrologix)
Potential Broad Pipeline of indications:
HIV :
HIV Combination therapy = BLA filing completed in May 2020 with rolling review
HIV Monotherapy = Protocol for pivotal Phase 3 trial filled
CANCER:
-Triple-Negative Breast = Phase 1b/2 trial underway with fast track destination
-Phase 2 basket trail underway for 22 solid tumors (Melanoma, Brain-glioblastoma, Throat, lung, stomach, colon, breast, testicular, ovarian, uterine, pancreas, bladder, among other indications.)
IMMUNOLOGY = Phase 1b/2 trial underway with Fast Track Destination
-GvHD = Phase 2 trial underway with Orphan Drug destination
-Nash = IND and Phase 2 protocol filed
-Coronavirus (COVID-19) = Patient treatment underway via Phase 2 and 2b/3 trials completed and emergency IND
Autoimmune ( multiple potential indications including Crohn’s disease, IBS (inflammatory bowel disease), MS (Multiple Sclerosis), Hashimoto’s thyroiditis, Vasculitis, Psoriasis, Polymyositis, Autoimmune Hepatitis, Grave’s disease, Sjogren’s syndrome, Myasthenia gravis).
CytoDyn is in discussions and seeking 510K for a Licensing Opportunities in the Mechanism of action: Proprietary gene secuencing, A.I.
Program = Prognostic / Indication = Prostate Cancer with a BLA filling completed in May 2020 with rolling review.
Plus Long Haulers trial application to start or application already in process.
Clinical Trial enrollment:
-Triple-Negative Breast Cancer
-COVID-19 Mild to Moderate
-COVID-19 Severe or Critical
Manuscript Accepted by infectious Diseases Society of America: Clinical Characteristics and outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab
Published: 20 October 2020
Leronlimab’s Mechanism of Action in COVID-19 Published: CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.
Published: February 01, 2021
Research on Critical Ill COVID-19 Patients Published in Journal of Translation Autoimmunity: Disruption of CCR5 Signaling to tread COVID-19-Associated Cytokine Storm: Case Series of Four Critical III Patients Treated with Leronlimab.
wenn nur 50% zutreffen...
Truth about CytoDyn-Leronlimab-PRO140(Vyrologix)
Potential Broad Pipeline of indications:
HIV :
HIV Combination therapy = BLA filing completed in May 2020 with rolling review
HIV Monotherapy = Protocol for pivotal Phase 3 trial filled
CANCER:
-Triple-Negative Breast = Phase 1b/2 trial underway with fast track destination
-Phase 2 basket trail underway for 22 solid tumors (Melanoma, Brain-glioblastoma, Throat, lung, stomach, colon, breast, testicular, ovarian, uterine, pancreas, bladder, among other indications.)
IMMUNOLOGY = Phase 1b/2 trial underway with Fast Track Destination
-GvHD = Phase 2 trial underway with Orphan Drug destination
-Nash = IND and Phase 2 protocol filed
-Coronavirus (COVID-19) = Patient treatment underway via Phase 2 and 2b/3 trials completed and emergency IND
Autoimmune ( multiple potential indications including Crohn’s disease, IBS (inflammatory bowel disease), MS (Multiple Sclerosis), Hashimoto’s thyroiditis, Vasculitis, Psoriasis, Polymyositis, Autoimmune Hepatitis, Grave’s disease, Sjogren’s syndrome, Myasthenia gravis).
CytoDyn is in discussions and seeking 510K for a Licensing Opportunities in the Mechanism of action: Proprietary gene secuencing, A.I.
Program = Prognostic / Indication = Prostate Cancer with a BLA filling completed in May 2020 with rolling review.
Plus Long Haulers trial application to start or application already in process.
Clinical Trial enrollment:
-Triple-Negative Breast Cancer
-COVID-19 Mild to Moderate
-COVID-19 Severe or Critical
Manuscript Accepted by infectious Diseases Society of America: Clinical Characteristics and outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab
Published: 20 October 2020
Leronlimab’s Mechanism of Action in COVID-19 Published: CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.
Published: February 01, 2021
Research on Critical Ill COVID-19 Patients Published in Journal of Translation Autoimmunity: Disruption of CCR5 Signaling to tread COVID-19-Associated Cytokine Storm: Case Series of Four Critical III Patients Treated with Leronlimab.
